The association of lipid levels with mortality in patients on chronic peritoneal dialysis

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2881-2892

  Habib, Arsalan N ^a   Baird, Bradley C ^a   Leypoldt, John K ^a,b   Cheung, Alfred K ^a,b   Goldfarb Rumyantzev, Alexander S ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Lipids; Mortality; Peritoneal dialysis; Triglycerides

Indexed keywords

ALBUMIN; CHOLESTEROL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ADULT; AGED; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 33749592422     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl272     Document Type: Article

References (34)

1. Foley RN, Parfrey PS, Sarnak MJ. The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]: S112-S119
2. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: 507-517
3. Zager PG, Nikolic J, Brown RH et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561-569
4. Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: Is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 2001; 38: S4-S7
5. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-1893
6. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin Nephrol 2001; 56: 221-230
7. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291: 451-459
8. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: The 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817
9. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
10. Fytili CI, Progia EG, Panagoutsos SA et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2002; 24: 623-630
11. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 2001; 38: S14-S19
12. Coresh J, Longenecker JC, Miller ER,3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9: S24-S30
13. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482
14. Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003; S113-S116
15. O'Riordan E, O'Donoghue DJ, Kalra PA, Foley RN, Waldek S. Changes in lipid profiles in nondiabetic, nonnephrotic patients commencing continuous ambulatory peritoneal dialysis. Adv Perit Dial 2000; 16: 313-316
16. Twardowski ZJ, Nolph KD, Prowant BF, Ryan L, Moore HL, Nielsen MP. Peritoneal equilibration test. Peritoneal Dial Bull 1987; 7: 138-147
17. Dupont W. Statistical Modeling for Biomedical Researchers Cambridge, Cambridge University Press, 2002
18. Greenberg JA. Hypothesis - the J-shaped follow-up relation between mortality risk and disease risk-factor is due to statistical confounding. Med Hypotheses 2002; 59: 568-576
19. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein P, Mittman N. The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20: 324-335
20. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
21. Fox CS, Longenecker JC, Powe NR et al. Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients. Clin Nephrol 2004; 61: 299-307
22. Wanner C, Krane V, Matz W et al. 2Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 2004; 27: 259-266
23. Kalantar-Zadeh K, Anker SD. Inflammation, cholesterol levels, and risk of mortality among patients receiving dialysis. JAMA 2004; 291: 1834; author reply 1834-1835.
24. Ravnskov U. Inflammation, cholesterol levels, and risk of mortality among patients receiving dialysis. JAMA 2004; 291: 1833-1834, author reply 1834-1835
25. Kaysen GA, Dubin JA, Muller HG, Rosales L, Levin NW, Mitch WE. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65: 1408-1415
26. Lim WH, Johnson DW, McDonald SP. Higher rate and earlier peritonitis in aboriginal patients compared to non-aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: Analysis of ANZDATA. Nephrology (Carlton) 2005; 10: 192-197
27. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 [Suppl 5]: 92-96
28. Johansson AC. Nutritional status in peritoneal dialysis: Studies in body composition, lipoprotein metabolism and peritoneal function. Scand J Urol Nephrol Suppl 2002; 7-31
29. Liberopoulos EN, Papavasiliou E, Miltiadous GA et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int 2004; 24: 580-589
30. Cressman MD, Hoogwerf BJ, Schreiber MJ, Cosentino FA. Lipid abnormalities and end-stage renal disease: Implications for atherosclerotic cardiovascular disease? Miner Electrolyte Metab 1993; 19: 180-185
31. Tschope W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 1993; 64: 354-358
32. Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 1999; 83: 13F-16F
33. Austin MA, McKnight B, Edwards KL et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101: 2777-2782
34. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163: 1077-1083